Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register account icon
S&P 500
7,609.78
(
0.13%
)
US TECH 100
29,812.00
(
0.34%
)
Dow Jones
51,307.79
(
0.45%
)
Brent Oil
95.26
(
-0.74%
)
Bitcoin
66,334.63
(
-7.05%
)
News Focus
News Focus
Post# of 828925
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (4) Keep Next 10 Report Keyboard Shortcuts
Replies (4) Next 10 Prev Next

exwannabe

Send PM Follow Ignore
Followers 91
Posts 20563
Boards Moderated 0
Alias Born 09/06/2006

exwannabe

Re: KRISGO post# 806692

Saturday, 01/03/2026 4:22:20 PM

Saturday, January 03, 2026 4:22:20 PM

Post# of 828925

Example: Lenacapavir (for HIV prevention), which likely sat in the same review cycle, received its formal MHRA press release on December 19, 2025.


Gemini, the gift that keeps on giving.

The Lenacapavir MAA never had a CHM meeting. It is just a reformulation of an existing medicine and had already been approved in the EU. MHRA rubber stamps these. The submission was sometime after Mid Sep 2025 and no CHM meeting since then discussed it.

Gemini just makes crap up to support a suggested argument,
Public Reply Private Reply New Post
Keep Last Read
Replies (4) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (4) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent NWBO News
More NWBO News